Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The Case for Aggregated Rehabilitation-Relevant Data across Health Care Systems and Settings.
Phys Ther
March 2025
Department of Physical Therapy, University of Nevada, Las Vegas, NV 89154, United States.
Health care value, quantified as outcome per unit cost, requires knowing which outcomes are influenced by which intervention at what cost. The value of rehabilitation is still largely unknown. Much of the reason for this limited evidence is historically poor standardization and collection of rehabilitation interventions, and objectively measured outcomes across care settings, care providers, and health care systems.
View Article and Find Full Text PDFThe search for a TNBC vaccine: the guardian vaccine.
Cancer Biol Ther
December 2025
School of Pharmacy, Queen's University Belfast, Belfast, UK.
Nearly 20 million people are diagnosed with cancer each year with breast cancer being the most common among women. Triple negative breast cancer (TNBC), defined by its no/low expression of ER and PR and lack of amplification of HER2, makes up 15-20% of all breast cancer cases. While patients overall have a higher response to chemotherapy, this subgroup is associated with the lowest survival rate indicating significant clinical and molecular heterogeneity demanding alternate treatment options.
View Article and Find Full Text PDFIndirect treatment comparison of oral sebetralstat and intravenous recombinant human C1 esterase inhibitor for on-demand treatment of hereditary angioedema attacks.
Allergy Asthma Clin Immunol
March 2025
University of Cincinnati, College of Medicine, Cincinnati, OH, USA.
Background: The goal of on-demand treatment for hereditary angioedema attacks is to halt attack progression to minimize morbidity and mortality. Four on-demand treatments have been approved thus far (ecallantide, icatibant, recombinant human C1 esterase inhibitor [rhC1INH], and plasma-derived C1INH). Results from the sebetralstat phase 3 KONFIDENT trial (NCT05259917) have been reported.
View Article and Find Full Text PDF'I was eager to do anything I could to improve the situation': a qualitative study of patients' experiences and views of prehabilitation for ovarian cancer surgery.
BMC Womens Health
March 2025
Nursing Directorate, Imperial College Healthcare NHS Trust, Charing Cross Hospital, Fulham Palace Road, London, UK.
Background: Prehabilitation has shown promise in improving post-operative outcomes for several solid tumour groups. However, prehabilitation programmes are not widely established. Patients with advanced ovarian cancer experience life changing debulking surgery and could benefit from prehabilitation.
View Article and Find Full Text PDFAre monocytes a preferable option to develop myeloid cell-based therapies for solid tumors?
J Exp Clin Cancer Res
March 2025
Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia.
In the last two decades, novel and promising cell-based therapies have populated the treatment landscape for haematological tumors. However, commonly exploited T and NK cell-based therapies show limited applicability to solid tumors. This is mainly given by the impaired tumor trafficking capability and limited effector activity of these cells within a highly immunosuppressive tumor microenvironment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!